feedback

Course Director

Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCO

University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Faculty

Philip Kantoff
Philip Kantoff, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, New York

William K. Oh
William K. Oh, MD

Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York

Charles J. Ryan
Charles J. Ryan, MD

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Jul-07
Expiration Date:2018-Jul-06
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in oncology merge evidence-based, practical instruction with elements of narrative medicine to explore the complex treatment landscape in prostate cancer.

Upon completion of this activity, participants should be better able to:
  • Analyze up-to-date data on the efficacy and safety of approved and investigational therapies and novel combinations for prostate cancer, and the clinical implications of these data.
  • Describe key current and planned clinical trials assessing hormone, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination in different settings of prostate cancer.
  • Develop treatment plans for patients with prostate cancer using the latest agents in appropriate sequences or combinations in accordance with up-to-date evidence and practice/expert recommendations, and based on consideration of the relevant tumor-, patient-, treatment-related factors and patient needs/preferences.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologic oncologists, and other clinicians involved in prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 07, 2017 - July 06, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant for Asana BioSciences, LLC.; Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Medivation, Inc.; Orion; and Sanofi.
Grant/Research Support from Asana BioSciences, LLC.; Bristol-Myers Squibb; Genentech, Inc.; and Lilly.

Faculty

Philip Kantoff, MD
Chairman of Medicine
George J. Bosl Chair in Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medicine
New York, New York

Philip Kantoff, MD, has a financial interest/relationship or affiliation in the form of:
Shareholder in Bellicum Pharmaceuticals, Inc.; Druggability Technologies (DRGT); Metamark; Placon Therapeutics; and Tarveda Therapeutics.
Advisory Board for BN Immunotherapeutics Inc.; Druggability Technologies (DRGT); Janssen Pharmaceuticals, Inc.; Metamark; New England Research Institutes; OncoCellMDx; Progenity, Inc.; Sanofi; Tarveda Therapeutics; and Thermo Fisher Scientific.
Other Financial or Material Support from Data Safety Monitoring Boards for F. Hoffmann-La Roche/Genentech, Inc. and Merck & Co., Inc.

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

William K. Oh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Churchill Pharmaceuticals; Inovio Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Remedica; and Sanofi Genzyme.
Shareholder in Checkpoint Therapeutics, Inc.

Charles J. Ryan, MD
Professor of Clinical Medicine and Urology
Thomas Perkins Distinguished Professor in Cancer Research
Program Leader, Genitourinary Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Charles J. Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Astellas Pharma, Inc.; Bayer Corporation; Ferring Pharmaceuticals Inc; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from Karyopharm Therapeutics.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6142-18-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.